开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

未开盘 12-16 15:59:38

1.930

+0.000

0.00%

最高1.980	最低1.900	成交量72.80万
今开1.920	昨收1.930	日振幅4.15%
总市值9.63亿	流通市值9.63亿	总股本4.99亿
成交额139.25万	换手率0.15%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.93,"timestamp":1765871978265,"preClose":1.93,"halted":0,"volume":728000,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.3988283843257457,"marketStatus":"未开盘","change":0,"latestTime":"12-16 15:59:38","open":1.92,"high":1.98,"low":1.9,"amount":1392530,"amplitude":0.041451,"askPrice":1.94,"askSize":13500,"bidPrice":1.93,"bidSize":9000,"shortable":0,"etf":0,"ttmEps":-0.42726121081047447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.93,"openAndCloseTimeList":[[1765848600000,1765857600000],[1765861200000,1765872000000]],"volumeRatio":1.119483,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939/wiki","defaultTab":"wiki","newsList":[{"id":"2591339909","title":"青海：中（藏）医药守正创新 可及性持续增强","url":"https://stock-news.laohu8.com/highlight/detail?id=2591339909","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591339909?lang=zh_cn&edition=full","pubTime":"2025-12-16 23:02","pubTimestamp":1765897320,"startTime":"0","endTime":"0","summary":"据了解，“十四五”以来，青海省持续提升中(藏)医药服务能力，先后落地实施国家中医区域医疗中心、中西医协同“旗舰”医院、中医特色重点医院等重大项目。全省60所综合医院和29所妇幼保健机构开展中(藏)医药服务，基层医疗卫生机构中(藏)医馆建设实现全覆盖，中藏医药服务可及性持续增强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-16/doc-inhaziez9722624.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-16/doc-inhaziez9722624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1515","159938","BK1574","BK1161"],"gpt_icon":0},{"id":"2591988977","title":"甘露特钠迎转机，复星医药拟控股绿谷医药推进其上市后临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2591988977","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591988977?lang=zh_cn&edition=full","pubTime":"2025-12-16 17:52","pubTimestamp":1765878774,"startTime":"0","endTime":"0","summary":"12月15日，复星医药宣布，控股子公司复星医药产业与绿谷（上海）医药科技有限公司（“绿谷医药”）及其现有相关股东共同签订相关投资协议，拟出资约14.12亿元控股收购绿谷医药。本次收购完成后，绿谷医药将成为复星医药控股子公司，其核心药品甘露特钠胶囊也将纳入复星医药创新药品管线，主要用于治疗轻度至中度阿尔茨海默病（AD）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163593128594.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593128594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK1574","BK0060","BK0196","BK1161","BK1515","159938","BK1191","09939","BK0239","BK0096","02196","BK0187","BK0175","BK0188","600196","BK0028","BK0012","BK1593"],"gpt_icon":0},{"id":"2591607815","title":"复星医药收购绿谷医药，阿尔兹海默病患者看到曙光？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591607815","media":"读懂财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591607815?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:49","pubTimestamp":1765874940,"startTime":"0","endTime":"0","summary":"　　“阿尔茨海默病药物研发的“死亡谷”里，一款曾被誉为国产创新药希望、又深陷科学争议的明星药物，正在等待它的救赎。”　　12月15日，复星医药宣布收购绿谷医药，其核心产品甘露特钠胶囊也将纳入复星医药创新药品管线。凭借着深厚的全球研发能力和中枢神经领域日益完善的创新药械矩阵，复星医药能否让这款命运多舛的药物重获新生，从而破解现有阿尔茨海默病治疗药物疗效欠佳的困局，成为行业关注的焦点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2025-12-16/doc-inhaysim8510706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK0188","BK0012","600196","BK0028","BK1161","BK0187","BK1515","BK0175","02196","BK0096","BK1593","BK0239","159938","BK1191","BK0196","09939","BK0060","BK0183"],"gpt_icon":0},{"id":"2591607273","title":"每日卖空追踪 | 同源康医药-B 12月16日卖空量成交2.9万股，卖空比例为1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591607273","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591607273?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:30","pubTimestamp":1765873828,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间12月16日，涨1.75%，卖空量成交2.9万股，较上一交易日减少51.26%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163431a6a8b683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163431a6a8b683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","09939","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2591022646","title":"东方财富证券：创新浪潮涌动下 关注医药板块修复与突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2591022646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591022646?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:25","pubTimestamp":1765873557,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方财富证券发布研报称，随着中国创新药License-out项目总金额创下新纪录，临床前项目占比持续保持高位，ADC、双/多抗、小核酸等新兴疗法，以及代谢领域中肥胖适应症等或为未来License-out项目的重点方向。东方财富证券主要观点如下：今年以来，在创新药、AI医疗的带动下，化学制药板块领涨医药板块估值水平接近最近10年历史平均水平。中国创新药十年变革主要得益于全面的监管改革、研发投入的增加以及战略性的全球化布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","SG9999014674.SGD","LU0307460666.USD","IE00BZ08YS42.EUR","LU2543165471.USD","LU1997244956.HKD","LU0588546209.SGD","09939","BK0188","LU2097828805.USD","BK0095","159938","BK0077","BK0028","LU2148510915.USD","BK1521","BK1191","LU1719994722.HKD","LU2328871848.SGD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU1064131003.USD","LU1997245177.USD","01177","LU0359202008.SGD","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU2495084118.USD","LU2097828714.EUR","300059","BK1583","IE00BZ08YT58.USD","LU2580892789.USD","06160","01276","LU1303224171.USD","LU1831875114.USD","161027","BK1500","LU2289578879.USD","BK1515","BK0196","LU2097828474.EUR","LU2097828557.USD","LU1770034418.SGD","BK1588","BK1589","LU1251922891.USD"],"gpt_icon":0},{"id":"2591220607","title":"同源康医药-B12月16日主力净流入356.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2591220607","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591220607?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:15","pubTimestamp":1765872916,"startTime":"0","endTime":"0","summary":"12月16日, 同源康医药-B股价涨1.75%，报收13.39元，成交金额2817.8万元，换手率0.58%，振幅5.47%，量比0.71。同源康医药-B今日主力资金净流入356.0万元，上一交易日主力净流出8.3万元。该股近5个交易日上涨2.29%，主力资金累计净流入823.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2204.8万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216161610a6a8a0b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216161610a6a8a0b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02410","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2591608402","title":"【券商聚焦】海通国际：医药板块短期承压 长期看好创新药产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2591608402","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591608402?lang=zh_cn&edition=full","pubTime":"2025-12-16 09:43","pubTimestamp":1765849420,"startTime":"0","endTime":"0","summary":"金吾财讯|海通国际发布研报指，本周恒生医疗保健指数下跌2.3%，跑输恒生指数1.8个百分点，主要受南下资金年底季节性结账影响。2025年初至今，该指数累计涨幅达68.3%，大幅跑赢恒生指数38.8个百分点。子板块中CXO/科研服务表现最佳，医疗器械跌幅最大。长期来看，机构看好业绩确定性强的互联网医疗、CXO/科研服务龙头，以及具备海外授权合作能力的头部Biotech。风险提示包括临床进展不及预期、集采政策风险及宏观环境不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216095428a4503682&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216095428a4503682&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SGXZ86797644.SGD","BK1583","00241","BK1574","BK1589","06978","LU0456827905.SGD","BK1571","BK1247","06618","LU0051755006.USD","BK1615","BK1161","BK1591","86618","02269","SGXZ62798434.SGD","BK1142","09939","BK1515"],"gpt_icon":0},{"id":"2591676206","title":"同仁堂回应磷虾油涉嫌造假；复星医药14.12亿元收购绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591676206","media":"21世纪经济报道","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591676206?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:34","pubTimestamp":1765841653,"startTime":"0","endTime":"0","summary":"资本市场复星医药：控股子公司拟出资14.12亿元投资绿谷医药12月15日，复星医药公告称，公司控股子公司复星医药产业拟出资共计14.12亿元投资绿谷医药，包括受让部分股权和认缴新增注册资本。完成后，公司将通过复星医药产业及SPV合计持有绿谷医药53%的股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216073706a6a6ce59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216073706a6a6ce59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","00867","BK1574","09939","BK1515","BK1161","02196","02565","BK1191"],"gpt_icon":0},{"id":"2591648625","title":"争议药物\"九期一\"获新生？复星医药14亿元收购绿谷医药重启临床与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648625","media":"蓝鲸财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591648625?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:51","pubTimestamp":1765795877,"startTime":"0","endTime":"0","summary":"此次收购案后，复星医药方面表示，甘露特钠胶囊重新开展商业化生产和销售前，还需补充完成目前尚在开展的上市后确证性临床试验并获得国家药品审评部门批准。本次收购完成后，复星医药将携绿谷医药团队在药品审评部门的指导下，有序严谨推进上市后确证性临床试验，以期尽快实现获批；并适时开展相关适应症的国际多中心临床试验，惠及更多阿尔茨海默病患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765795546434638047","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK0096","BK1515","BK0183","BK0239","BK1593","BK0196","BK0187","BK0175","BK1574","BK0012","BK0028","09939","02196","BK0060","BK0188","600196","159938","BK1191"],"gpt_icon":1},{"id":"2591460847","title":"京东健康举行即时零售2025品牌增长大会 以超级医药供应链重构健康消费未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2591460847","media":"21世纪经济报道","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591460847?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:09","pubTimestamp":1765793357,"startTime":"0","endTime":"0","summary":"12月11日，以“启新篇 筑未来”为主题的京东健康即时零售2025品牌增长大会在北京隆重召开。会上，京东健康即时零售业务部平台秒送业务负责人详细介绍了这一能力体系的具体构成。她表示，科学与消费者洞察驱动的产品创新，结合京东健康这样的全域零售平台，能为品牌带来可持续的增长动力。展望2026年，京东健康宣布在即时零售领域，将聚焦专业化赛道，持续深化供应链能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215181237a44da90a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215181237a44da90a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1142","BK1574","LU0456827905.SGD","BK1591","BK1583","SGXZ62798434.SGD","BK1515","SGXZ86797644.SGD","09939","86618","BK1247","BK1571","BK1589","LU0051755006.USD","06618","BK1615","BK1161"],"gpt_icon":0},{"id":"2591612068","title":"复星医药：控股子公司拟出资14.12亿元投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612068","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612068?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:43","pubTimestamp":1765791813,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月15日，复星医药(600196.SH)公告称，公司控股子公司复星医药产业拟出资共计14.12亿元投资绿谷医药，包括受让部分股权和认缴新增注册资本。完成后，公司将通过复星医药产业及SPV合计持有绿谷医药53%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153591807093.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591807093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1191","BK0012","BK0096","BK1574","BK1515","09939","BK0060","BK0188","BK0175","BK0239","BK0196","600196","BK0183","BK0187","BK0028","02196","159938","BK1161"],"gpt_icon":0},{"id":"2591625600","title":"3家药企因下游合作方“不合规交易行为”公开致歉","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625600","media":"一拾药讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591625600?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:35","pubTimestamp":1765791351,"startTime":"0","endTime":"0","summary":"近日，河南省医药集中采购平台公布了3家药企发布的致歉声明。分别为哈尔滨誉衡制药、吉林四环制药、珠海经济特区粤康医药三家企业的公开致歉声明，原因均为其配送商或代理商存在不合规交易行为。珠海经济特区粤康医药则因其注射用头孢呋辛钠的代理商违规，被预评为“特别严重失信”。这一现象反映出，在医药招采信用评价制度下，药企对合作方的合规管理已与其自身信用直接挂钩，下游一旦违规，药企也难逃责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215183743a44dbf01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215183743a44dbf01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","01477","BK1161","BK1191","09939","00460","BK1574","BK1600","BK1515"],"gpt_icon":0},{"id":"2591649007","title":"医药日报：复宏汉霖新适应症获优先审评，君实生物双抗ADC出海获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649007","media":"药融链接","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591649007?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:06","pubTimestamp":1765789608,"startTime":"0","endTime":"0","summary":"君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。02产品注册与审批复宏汉霖：其产品斯鲁利单抗注射液新增适应症的上市申请已获受理，并被纳入优先审评程序。04国际合作与出海君实生物：其针对EGFR/HER3的双特异性抗体偶联药物用于治疗晚期实体瘤的临床试验申请，已获得美国FDA批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1574","BK1583","09939","01877","BK1515","02696","BK1161"],"gpt_icon":0},{"id":"2591611929","title":"香港医疗设备采购商柏威医药(AED.US)申请美股IPO，拟筹资700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591611929","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591611929?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:55","pubTimestamp":1765788951,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，总部位于香港的医疗设备和软件采购商柏威医药于上周四向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多700万美元资金。该公司计划以每股7至9美元的价格发行90万股股票，筹资700万美元。按拟议发行区间的中值计算，柏威医药的市值将达到8700万美元。这家总部位于香港的公司成立于2003年，在截至2025年3月31日的12个月内录得营业收入2500万美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159873","BK1161","09939","159938","BK1515"],"gpt_icon":0},{"id":"2591861598","title":"12月15日三生国健跌5.83%，交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591861598","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591861598?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:35","pubTimestamp":1765784122,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日三生国健跌5.83%，收盘报60.7元，换手率0.85%，成交量5.24万手，成交额3.22亿元。重仓三生国健的前十大公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为70.27。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","BK0239","BK1515","688336","159938","BK1574"],"gpt_icon":0},{"id":"2591691376","title":"恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591691376?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:11","pubTimestamp":1765768311,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒生医疗保健指数跌幅扩大至2.75%，医药股普遍走低，科伦博泰生物(06990)跌7.07%，百济神州(06160)跌5.35%，复宏汉霖(02696)跌5.32%，荣昌生物(09995)跌4.05%，康方生物(09926)跌3.61%。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","HK0000165453.HKD","LU0348767384.USD","LU0417516571.SGD","BK1574","LU0348735423.USD","LU0561508036.HKD","LU0196878994.USD","LU2476274308.USD","LU1961090484.USD","LU0634319403.HKD","LU0588546209.SGD","LU0348825331.USD","LU1251922891.USD","159938","LU0348783233.USD","BK1583","LU0417516738.SGD","09939","IE00BPRC5H50.USD","LU2488822045.USD","BK1161","09995","06990","IE00B543WZ88.USD","LU2476274720.SGD","LU1303224171.USD","LU2399975544.HKD","LU1969619763.USD","LU0348784397.USD","LU0540923850.HKD","BK1515","LU0307460666.USD","BK1588","LU1719994722.HKD","06160","LU0348766576.USD","159506","LU0348827113.USD","LU1770034418.SGD","LU2328871848.SGD","09926","LU1794554557.SGD","BK1500","02696","IE00B5MMRT66.SGD","LU0417516902.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"2591640278","title":"医药行业周报：医药板块逐步筑底","url":"https://stock-news.laohu8.com/highlight/detail?id=2591640278","media":"西南证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591640278?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:06","pubTimestamp":1765764387,"startTime":"0","endTime":"0","summary":"投资要点行情回顾：本周医药生物指数下跌1.04%，跑输沪深300指数0.96个百分点，行业涨跌幅排名第18。中央经济工作会议12月10日至11日在北京举行，首次明确提出优化药品集中采购，深化医保支付方式改革。药品在原集采最低价中标基础上优化，叠加药品支付端改善，医药商业化空间或将进一步扩大。本次集采共纳入55种药品，中标率57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215100647a6a30153&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215100647a6a30153&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","BK1583","06160","LU0588546209.SGD","LU1719994722.HKD","09939","BK1500","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","LU1251922891.USD","LU1770034418.SGD","BK1515","BK1161","BK1574","BK1588"],"gpt_icon":0},{"id":"2591956296","title":"港股开盘 | 恒指低开1% 医药板块跌幅居前 歌礼制药(01672)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591956296","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591956296?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:30","pubTimestamp":1765762255,"startTime":"0","endTime":"0","summary":"恒生指数低开1%，恒生科技指数跌1.34%。盘面上，辅助生殖概念活跃，三胎概念股锦欣生殖开涨约3%；医药板块跌幅居前，歌礼制药跌超5%。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f81ff915a0c110277ba56cf9ecd1a11a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","BK1574","BK4614","YANG","BK1515","HSI","MHImain","HSImain","MCHmain","159938","HHImain","513600","02833","01672","09939","01477","BK1161"],"gpt_icon":0},{"id":"2591466597","title":"A股医药股，利好来了！今晚，密集公告！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591466597","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591466597?lang=zh_cn&edition=full","pubTime":"2025-12-14 20:39","pubTimestamp":1765715940,"startTime":"0","endTime":"0","summary":"多只医药股发布利好消息。　　今晚，九安医疗公告，美国子公司四联检、三联检产品获得美国FDA上市前通知，涉及的产品包括甲型流感、乙型流感、COVID-19及RSV呼吸道合胞病毒四联检测家用试剂盒等。　　开源证券表示，当前纳入医保+商保的创新药大多处于未放量以及低基数阶段，随着医保支持创新药的政策红利持续释放，纳入双目录的创新药收入有望快速提升，患者有望持续受益，同时相关创新药企也随之迎来弹性增长。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-14/doc-inhauqsx4667847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399300","BK1515","09939","BK1161","BK1574","159938","159982"],"gpt_icon":0},{"id":"2591650105","title":"佐力药业最新公告：拟3.56亿元收购未来医药多种微量元素注射液资产组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650105","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650105?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:39","pubTimestamp":1765701597,"startTime":"0","endTime":"0","summary":"佐力药业公告称，公司于12月12日与西藏未来生物医药股份有限公司及其两家全资子公司许昌未来制药有限责任公司和合肥市未来药物开发有限公司签署了《多种微量元素注射液资产组收购协议书》，拟以总价（含税）3.56亿元收购其多种微量元素注射液资产组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400003927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK1161","09939","159938","300181","BK1515","BK0042","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":-0.081},{"period":"3month","weight":-0.2577},{"period":"6month","weight":0.2781},{"period":"1year","weight":0.9109},{"period":"ytd","weight":0.9897}],"compareEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":-0.0679},{"period":"3month","weight":-0.0622},{"period":"6month","weight":0.086},{"period":"1year","weight":0.2748},{"period":"ytd","weight":0.258}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.188252}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}